Top News

Promising Phase I interim data for ExPEC vaccine program triggers first milestone payment in clinical co-development with Janssen

SBA Member News, 01.02.2015

GlycoVaxyn, a leader in the development of innovative conjugate vaccines, announced recently that it has received the first milestone in its clinical co-development with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, of the vaccine candidate aimed to prevent infections caused by Extraintestinal Pathogenic Escherichia coli (ExPEC or E. coli).


Next Event


Community Login

Bachem Holding AG

 Wissenschaft im Gespraech | Den Naturwissenschaften fehlt der Nachwuchs | Schweizer Radio DRS

The potential in the land

LRC TriCEPS™ technology

BBC - End of Drug Discovery